Jennifer A. Woyach

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute — United States

Medicine · Health Sciences

61h-index17.9kcitations597works5.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(518), Lymphoma Diagnosis and Treatment(258), Immunodeficiency and Autoimmune Disorders(99), Chronic Myeloid Leukemia Treatments(98), Advanced Breast Cancer Therapies(58)

Publications597 total

A Phase I Study of Combination Duvelisib and Nivolumab in Patients With Diffuse Large B‐Cell Lymphoma, Transformed Follicular Lymphoma, and Richter Transformation
European Journal Of Haematology·2025Open Access
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Journal of Clinical Oncology·2025· 2 citedOpen Access
Supplementary Table S1 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025Open Access
Supplementary table S2 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025Open Access
Supplementary Methods S1 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025Open Access
Supplementary Table S3 from B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
2025Open Access
PKCβ Inhibitor MS-553 Displays Preclinical Efficacy in Both Treatment-Naïve and BTK Inhibitor–Resistant Chronic Lymphocytic Leukemia
Blood Cancer Discovery·2025· 1 cited
The bromodomain and extra-terminal domain protein BRD4 promotes both self renewal and inflammation in TET2 mutated clonal hematopoiesis
Blood·2025Open Access
Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies
Blood·2025
Safety and efficacy of transposon, BAFF-ligand directed chimeric antigen receptor T cells (LMY-920) with pre-apheresis obinutuzumab for patients with Relapsed/Refractory chronic lymphocytic leukemia and small lymphocytic lymphoma
Blood·2025
Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study
Blood·2025
Dysregulation of NF-kb and p73 signal axes in chronic lymphocytic leukemia with gain-of-function mutated p53
Blood·2025Open Access
Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease
Blood·2025Open Access
Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study
Blood·2025
Updates of R/R CLL with prior exposure to Bruton's tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor
Blood·2025
A phase II multi-institutional Study evaluating the safety and efficacy of the combination of lisocabtagene maraleucel and zanubrutinib in patients with richter transformation
Blood·2025Open Access
Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Blood·2025Open Access
Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia
Blood·2025Open Access
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia
Blood·2025· 1 citedOpen Access
Treatment patterns for del(17P)/mutated <i>TP53</i> or relapsed/refractory (R/R) CLL among experts and lower-volume treaters.
JCO Oncology Practice·2025
page 1 of 30Next →

Frequent Co-authors

John C. Byrd(34), Amy J. Johnson(19), Farrukh T. Awan(16), Kami J. Maddocks(13), Amy S. Ruppert(12), Jeffrey A. Jones(12), Gerard Lozanski(11), Kerry A. Rogers(11), Jennifer R. Brown(11), Richard R. Furman(10), William G. Wierda(9), Joseph M. Flynn(9), Leslie A. Andritsos(9), Samantha Jaglowski(8), Nyla A. Heerema(8), John M. Pagel(8), Lisa L. Smith(8), Kristie A. Blum(7), Steven Coutré(7), Paolo Ghia(7)